Evolution of Antibiotic Resistance in Enteric Bacteria

肠道细菌抗生素耐药性的演变

• 批准号: 6914651
• 负责人: Margaret A. Riley
• 金额: $ 32.39万
• 依托单位: UNIVERSITY OF MASSACHUSETTS AMHERST
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6914651
• 关键词: Australia; Mammalia; R factors; antibiotics; bacterial genetics; beta lactam antibiotic; drug resistance; enteric bacteria; feces analysis; gene environment interaction; gene mutation; genetic library; genetic screening; hospitals; host organism interaction; laboratory mouse; microorganism population study; northern blottings; polymerase chain reaction; streptomycin; sulfamethoxazole; wild animals

DESCRIPTION (provided by applicant): The development and spread of bacterial antibiotic resistance has emerged as a major public health concern. Pathogenic bacteria once easily controlled by antimicrobial drugs now frequently fail to respond to most antibiotics. Most research on the causes and consequences of antibiotic resistance focuses on clinical isolates of pathogenic bacteria, i.e. isolates from infected humans in hospitals. These studies reveal the diversity of resistance mechanisms and genes, the genetic details of how resistance spreads between bacterial lineages and provide estimates of the speed with which such spread occurs in hospital settings. Such clinically based studies play an essential role in efforts to track the course of antibiotic resistance evolution and suggest the priority of drug use for particular pathogens. However, these studies suffer from two critical omissions. First, R genes characterized from clinical isolates represent a small fraction of the existing diversity of R genes. It is now clear that antibiotic resistance predates the human mediated use of antibiotics and it is equally clear that for every drug humans discover, design or develop, it is almost certainly the case that microbes already possess a defensive mechanism and it is only a matter of time before that mechanism is transferred to a human pathogen. It is critical to have a more complete understanding of the diversity of existing resistance mechanisms if we are to successfully plan antimicrobial strategies. Second, these studies ignore the complex ecological and evolutionary pressures that bacteria and their resistance genes experience in nature (in addition to those resulting from human-mediated antibiotic use). This information is critical to the development of rational treatment therapies. The goal of this research is to explore and contrast the evolution of antibiotic resistance in natural and clinical populations of enteric bacteria and to apply these data to efforts aimed at the development of more effective antibiotic therapies. We propose here the first "comprehensive" survey of antibiotic resistance evolution in natural populations of bacteria. What makes our study comprehensive is the combined focus on antibiotic resistance phenotypes, genotypes, levels of genetic variation and divergence, estimates of resistance-associated fitness effects and the use of these data to inform existing antibiotic therapies and contribute to the design of more rational or novel therapies.

描述(由申请人提供)：细菌抗生素耐药性的发展和传播已成为一个主要的公共卫生问题。病原菌曾经很容易被抗菌药物控制，但现在往往对大多数抗生素都不起作用。大多数关于抗生素耐药性的原因和后果的研究都集中在临床分离的病原菌上，即从医院感染的人身上分离出来的细菌。这些研究揭示了耐药性机制和基因的多样性，即耐药性如何在细菌谱系之间传播的遗传细节，并提供了对这种传播速度在医院环境中发生的估计。这类以临床为基础的研究在追踪抗生素耐药性演变过程并建议对特定病原体优先使用药物方面发挥了至关重要的作用。然而，这些研究有两个关键的遗漏。首先，来自临床分离株的R基因只占现有R基因多样性的一小部分。现在很明显，抗生素耐药性早于人类中介使用抗生素，同样明显的是，对于人类发现、设计或开发的每一种药物，几乎可以肯定的是，微生物已经拥有一种防御机制，这种机制转移到人类病原体身上只是个时间问题。如果我们要成功地规划抗菌策略，对现有耐药机制的多样性有一个更完整的了解是至关重要的。其次，这些研究忽视了细菌及其耐药基因在自然界中所经历的复杂的生态和进化压力(除了人类介导的抗生素使用造成的压力之外)。这些信息对开发合理的治疗方法至关重要。这项研究的目标是探索和比较肠道细菌自然和临床种群中抗生素耐药性的演变，并将这些数据应用于旨在开发更有效的抗生素疗法的努力。在这里，我们提出了第一个关于细菌自然种群中抗生素耐药性进化的“全面”调查。使我们的研究全面的是对抗生素耐药性表型、基因型、遗传变异和分歧水平、耐药性相关适应效应的估计以及这些数据的使用来为现有的抗生素疗法提供信息，并有助于设计更合理或更新的疗法。